Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
-
REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
-
REGULATORY Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
-
REGULATORY Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
-
BUSINESS Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
-
REGULATORY LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
-
BUSINESS Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
-
ORGANIZATION Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
-
BUSINESS Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
-
REGULATORY PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
December 5, 2016
-
INTERVIEW Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
December 2, 2016
-
REGULATORY Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
-
REGULATORY Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
-
REGULATORY “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
-
BUSINESS Signs of Growth in Prescribing SGLT-2 Inhibitors with Favorable Environment Change
November 30, 2016
-
BUSINESS Ono to Offer New Invoice Prices for Opdivo Early on to Avoid Distribution Confusion
November 29, 2016
-
REGULATORY Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
-
BUSINESS Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
-
REGULATORY Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
-
BUSINESS 27 Japan Drug Makers Eke Out Profit despite Logging Lower Sales on FX, Price Cuts: Jiho Tally
November 24, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…